Trial Profile

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Mar 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
Indications Multiple myeloma
Focus Adverse reactions
Sponsors Amgen; Onyx Pharmaceuticals

Most Recent Events

01 Feb 2021 Protocol of the trial was amended as cohort 1 was suspended due to serious adverse events and cohort four was added.
01 Feb 2021 Results (n=33) assessing safety of carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma, published in the American Journal of Hematology
01 Nov 2019 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com